Objective To analyze the effect of treatment of non-nephrotic syndrome IgA nephropathy with Shenyanning. Methods 100 patients with non-nephrotic syndrome IgA nephropathy were divided into objective group and the control group. The Shenyanning was additional used in the objective group, and the control used traditional drug only. The difference of the clinical symptoms and the laboratory examination indexes between the two groups were compared. Results The clinical symptoms of the objective group was better than the control group. There was a significant development in the laboratory examination indexes in all the cases. However, the objective group get the more positive results than that in the control group. Conclusion It would get a satisfactory effect to use Shenyanning in the treatment of non-nephrotic syndrome IgA nephropathy, with the more positive in the field of clinical symptoms and the laboratory examination indexes.%目的探讨肾炎宁在改善非肾病综合征IgA肾病患者症状和尿红细胞计数、内生肌酐清除率以及24h尿蛋白量指标方面的效果。方法以2012年5月～2012年10月间来我院治疗非肾病综合征IgA肾病的患者100例为研究对象，随机分为实验组（50例）与对照组（50例），实验组采用肾炎宁结合血管紧张素转化酶抑制药卡托普利治疗，对照组仅使用卡托普利治疗，统计分析比较两组患者在症状和实验室检查指标尿红细胞计数、内生肌酐清除率以及24h尿蛋白量方面的差异。结果两组患者在内生肌酐清除率方面无明显差异，除此之外，实验组与对照组相比较，实验组患者疗效较好，治疗结果为显效和有效的患者数量明显多于对照组，治疗后实验组患者尿红细胞计数及24h尿蛋白量方面明显改善，两组患者治疗后实验室检查指标差异显著，经检验其差异均有统计学意义（P＜0.05）。结论采用肾炎宁结合血管紧张素转化酶抑制药卡托普利治疗非肾病综合征IgA肾病患者，患者症状和尿红细胞计数及24h尿蛋白量指标改善明显，且治疗效果明显优于单纯使用西药治疗，可临床应用。
展开▼
